Gilead Sciences (GILD) Change in Accured Expenses (2009 - 2026)

Gilead Sciences (GILD) has reported Change in Accured Expenses for 18 consecutive years, with $338.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Accured Expenses rose 303.61% year-over-year to $338.0 million; the trailing twelve-month figure through Jun 2026 stood at $52.0 million (up 10.64% YoY), and the FY2025 full-year result was $6.0 million, down 94.44% from the prior year.
• Change in Accured Expenses climbed to $338.0 million in Q2 2026 per GILD's latest filing, from -$702.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $811.0 million in Q3 2025 and bottomed at -$1.7 billion in Q1 2022.
• Historically, Change in Accured Expenses has averaged -$31.5 million across 5 years, with a median of $101.0 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses surged 1348.0% in 2022, then slumped 229.51% in 2025.
• Over 5 years, Change in Accured Expenses stood at $356.0 million in 2022, then dropped by 10.96% to $317.0 million in 2023, then declined by 3.79% to $305.0 million in 2024, then plunged by 229.51% to -$395.0 million in 2025, then soared by 185.57% to $338.0 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $338.0 million, -$702.0 million, and -$395.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.